ANCOVA analysis of covariance ANP Atrial-derived natriuretic peptides ARB Angiotensin receptor blockers ARNI Angiotensin receptor neprilysin inhibitor AST Aspartate aminotransferase AT1 Angiotensin type 1 AUC Area under the serum concentration-time curve Area trial the serum concentration-time curve from time zero to AUC0-t time t Area trial the serum concentration-time curve from time zero to AUCinf infinity Area Under the Plasma Concentration-time profile from time zero AUClast to the time of the last quantifiable concentration Area under the plasma concentration-time curve for a dosing AUCtau interval AUEC Area under the effect curve Aβ Amyloid beta peptides BID Bis in die / Twice a day BMI body mass index BNP brain natriuretic peptide BP blood pressure CABG coronary artery bypass CAD coronary artery disease CCS clinical composite score cGMP Cyclic guanosine monophosphate CHF congestive heart failure CI Confidence interval
ANCOVA analysis of covariance ANP Atrial-derived natriuretic peptides ARB Angiotensin receptor blockers ARNI Angiotensin receptor neprilysin inhibitor AST Aspartate aminotransferase AT1 Angiotensin type 1 AUC Area under the serum concentration-time curve AUC0-t Area the serum concentration-time curve from time zero to time t AUCinf Area the serum concentration-time curve from time zero to infinity AUClast Area Under the Plasma Concentration-time profile from time zero to the time of the last quantifiable concentration AUCtau Area under the plasma concentration-time curve for a dosing interval AUEC Area under the effect curve Aβ Amyloid beta peptides BID Bis in die / Twice a day BMI body mass index BNP brain natriuretic peptide BP blood pressure CABG coronary artery bypass CAD coronary artery disease CCS clinical composite score cGMP Cyclic guanosine monophosphate CHF congestive heart failure CI Confidence interval trial trial
auspar-sacubitril-valsartan-salt-complex-160923-cer.docx